News

GlobalData on MSN6d
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Contract Pharma6d
Rznomics & Eli Lilly Enter Global Licensing Agreement
Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership
Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...
Insider Monkey5d
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA ... a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic ...
Investing Snacks3d
Lilly Hears Opportunity in $1.3B RNA Therapy Deal
Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...
PipelineReview.com6d
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today ...